2016 Fear vs Hope: Gene Editing— Terrible turning point?
By Pete Shanks,
Deccan Chronicle
| 01. 01. 2017
The next year may represent our best chance to prevent the rise of a modern, uncontrolled and dangerously ill-considered techno-eugenics.
If new “gene editing” tools can be used to treat people who are sick, that would be a hugely welcome development. But applying them to human reproduction could all too easily open the door to a world of genetic haves and have-nots. Will it be possible for the distinction between responsible and irresponsible applications of human genetic technologies to hold, in policy and in practice? There is hope, but the signals from 2016 are very worrying.
One year ago, the U.S. National Academies Summit on Human Gene Editing ended with a consensus statement that proceeding with inheritable (germline) gene editing would be “irresponsible” until both the science was proven and there was “broad societal consensus about the appropriateness of the proposed application.”
It didn’t take long for that to seem wildly optimistic. Even before that announcement, and in complete secrecy, a rogue American scientist had defied authorities by using Mexican facilities to create a baby for a Jordanian couple using...
Related Articles
By Rob Stein, NPR [cites CGS' Katie Hasson] | 08.06.2025
A Chinese scientist horrified the world in 2018 when he revealed he had secretly engineered the birth of the world's first gene-edited babies.
His work was reviled as reckless and unethical because, among other reasons, gene-editing was so new...
By Kristel Tjandra, Genetic Engineering & Biotechnology News | 07.30.2025
CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on various fronts. But getting CRISPR experiments right in the lab isn’t simple...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...